annual meeting program - American Society of Clinical Oncology

8:00 AM - 9:30 AM
CLINICAL SCIENCE SYMPOSIUM
Molecularly Targeted Trials in Lung Cancer
Location: E Hall D1
CME credit: 1.5
Track(s): Lung Cancer
Saturday, June 5, 2010
Marvaretta Miesha Stevenson, MD—Co-Chair
Duke University Medical Center
Heather A. Wakelee, MD—Co-Chair
Stanford University
8:00 AM Randomized, open label, phase III trial of figitumumab in combination with
paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with
non-small cell lung cancer (NSCLC). (Abstract #7500)
J. Jassem, C. J. Langer, D. D. Karp, T. Mok, R. J. Benner, S. J. Green, K. Park,
S. Novello, J. Strausz, A. Gualberto
Discussion
8:15 AM D. Ross Camidge, MD, PhD (Abstract #7500)
University of Colorado, Denver
IGF1R: Where Do We Go from Here?
8:30 AM A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist
monoclonal antibody, in combination with carboplatin and paclitaxel in
patients with advanced NSCLC. (Abstract #LBA7501)
J. Von Pawel, J. H. Harvey, D. R. Spigel, M. Dediu, M. Reck, C. L. Cebotaru,
E. Kumm, G. Gallant, N. Fox, D. R. Camidge
Discussion
8:45 AM Bruce E. Johnson, MD (Abstract #LBA7501)
Dana-Farber Cancer Institute
Where Does This TRAIL Lead Us?
9:00 AM Results from ARQ 197-209: A global randomized placebo-controlled phase II
clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in
previously treated EGFR inhibitor-naive patients with locally advanced or
metastatic non-small cell lung cancer (NSCLC). (Abstract #LBA7502)
J. H. Schiller, W. L. Akerley, W. Brugger, D. Ferrari, E. G. Garmey, D. E. Gerber,
S. V. Orlov, R. Ramlau, J. Von Pawel, L. V. Sequist
Discussion
9:15 AM Ravi Salgia, MD, PhD (Abstract #LBA7502)
The University of Chicago
Combinations of Targeted Agents
85
SATURDAY